nodes	percent_of_prediction	percent_of_DWPC	metapath
Pomalidomide—TNF—glaucoma	0.383	0.678	CbGaD
Pomalidomide—PTGS2—glaucoma	0.182	0.322	CbGaD
Pomalidomide—CYP1A2—Betaxolol—glaucoma	0.0451	0.197	CbGbCtD
Pomalidomide—CYP3A4—Pilocarpine—glaucoma	0.0265	0.116	CbGbCtD
Pomalidomide—ABCB1—Timolol—glaucoma	0.0254	0.111	CbGbCtD
Pomalidomide—CYP1A2—Clonidine—glaucoma	0.0247	0.108	CbGbCtD
Pomalidomide—ABCB1—Clonidine—glaucoma	0.0216	0.0942	CbGbCtD
Pomalidomide—CYP3A4—Brinzolamide—glaucoma	0.0208	0.0907	CbGbCtD
Pomalidomide—CYP3A4—Dorzolamide—glaucoma	0.0201	0.0876	CbGbCtD
Pomalidomide—CYP3A4—Methazolamide—glaucoma	0.0179	0.0781	CbGbCtD
Pomalidomide—CYP3A4—Acetazolamide—glaucoma	0.0143	0.0624	CbGbCtD
Pomalidomide—CYP3A4—Clonidine—glaucoma	0.0129	0.0564	CbGbCtD
Pomalidomide—Thalidomide—TNF—glaucoma	0.00161	0.441	CrCbGaD
Pomalidomide—Lenalidomide—PTGS2—glaucoma	0.00128	0.35	CrCbGaD
Pomalidomide—Thalidomide—PTGS2—glaucoma	0.000765	0.209	CrCbGaD
Pomalidomide—Infection—Travoprost—glaucoma	0.000262	0.00168	CcSEcCtD
Pomalidomide—Headache—Methazolamide—glaucoma	0.000261	0.00168	CcSEcCtD
Pomalidomide—Breast disorder—Timolol—glaucoma	0.000261	0.00168	CcSEcCtD
Pomalidomide—Cardiac disorder—Clonidine—glaucoma	0.000261	0.00168	CcSEcCtD
Pomalidomide—Arthralgia—Pilocarpine—glaucoma	0.000261	0.00168	CcSEcCtD
Pomalidomide—Anxiety—Pilocarpine—glaucoma	0.00026	0.00167	CcSEcCtD
Pomalidomide—Nausea—Levobunolol—glaucoma	0.000259	0.00166	CcSEcCtD
Pomalidomide—Infection—Brinzolamide—glaucoma	0.000259	0.00166	CcSEcCtD
Pomalidomide—Nervous system disorder—Travoprost—glaucoma	0.000258	0.00166	CcSEcCtD
Pomalidomide—Nasopharyngitis—Timolol—glaucoma	0.000258	0.00166	CcSEcCtD
Pomalidomide—Epistaxis—Betaxolol—glaucoma	0.000257	0.00165	CcSEcCtD
Pomalidomide—Skin disorder—Travoprost—glaucoma	0.000256	0.00165	CcSEcCtD
Pomalidomide—Hyperhidrosis—Dorzolamide—glaucoma	0.000256	0.00164	CcSEcCtD
Pomalidomide—Nervous system disorder—Brinzolamide—glaucoma	0.000255	0.00164	CcSEcCtD
Pomalidomide—Angiopathy—Clonidine—glaucoma	0.000255	0.00164	CcSEcCtD
Pomalidomide—Rash—Latanoprost—glaucoma	0.000255	0.00164	CcSEcCtD
Pomalidomide—Dermatitis—Latanoprost—glaucoma	0.000254	0.00164	CcSEcCtD
Pomalidomide—Mediastinal disorder—Clonidine—glaucoma	0.000253	0.00163	CcSEcCtD
Pomalidomide—Headache—Latanoprost—glaucoma	0.000253	0.00163	CcSEcCtD
Pomalidomide—Skin disorder—Brinzolamide—glaucoma	0.000253	0.00162	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Brimonidine—glaucoma	0.000253	0.00162	CcSEcCtD
Pomalidomide—Confusional state—Pilocarpine—glaucoma	0.000252	0.00162	CcSEcCtD
Pomalidomide—Decreased appetite—Acetazolamide—glaucoma	0.000251	0.00161	CcSEcCtD
Pomalidomide—Insomnia—Brimonidine—glaucoma	0.000251	0.00161	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Acetazolamide—glaucoma	0.000249	0.0016	CcSEcCtD
Pomalidomide—Fatigue—Acetazolamide—glaucoma	0.000249	0.0016	CcSEcCtD
Pomalidomide—Infection—Pilocarpine—glaucoma	0.000248	0.0016	CcSEcCtD
Pomalidomide—Nausea—Methazolamide—glaucoma	0.000248	0.00159	CcSEcCtD
Pomalidomide—Dyspnoea—Brimonidine—glaucoma	0.000247	0.00159	CcSEcCtD
Pomalidomide—Mental disorder—Clonidine—glaucoma	0.000246	0.00158	CcSEcCtD
Pomalidomide—Thrombocytopenia—Pilocarpine—glaucoma	0.000245	0.00157	CcSEcCtD
Pomalidomide—Hyperhidrosis—Pilocarpine—glaucoma	0.000242	0.00155	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Dorzolamide—glaucoma	0.000241	0.00155	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Travoprost—glaucoma	0.00024	0.00154	CcSEcCtD
Pomalidomide—Insomnia—Dorzolamide—glaucoma	0.000239	0.00154	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Brimonidine—glaucoma	0.000239	0.00154	CcSEcCtD
Pomalidomide—Fatigue—Brimonidine—glaucoma	0.000239	0.00154	CcSEcCtD
Pomalidomide—Feeling abnormal—Acetazolamide—glaucoma	0.000238	0.00153	CcSEcCtD
Pomalidomide—Hypersensitivity—Apraclonidine—glaucoma	0.000238	0.00153	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Brinzolamide—glaucoma	0.000237	0.00152	CcSEcCtD
Pomalidomide—Pain—Brimonidine—glaucoma	0.000237	0.00152	CcSEcCtD
Pomalidomide—Dyspnoea—Dorzolamide—glaucoma	0.000236	0.00152	CcSEcCtD
Pomalidomide—Insomnia—Brinzolamide—glaucoma	0.000235	0.00151	CcSEcCtD
Pomalidomide—Muscle spasms—Clonidine—glaucoma	0.000235	0.00151	CcSEcCtD
Pomalidomide—Dyspnoea—Travoprost—glaucoma	0.000235	0.00151	CcSEcCtD
Pomalidomide—Upper respiratory tract infection—Timolol—glaucoma	0.000232	0.00149	CcSEcCtD
Pomalidomide—Dyspnoea—Brinzolamide—glaucoma	0.000232	0.00149	CcSEcCtD
Pomalidomide—Asthenia—Apraclonidine—glaucoma	0.000232	0.00149	CcSEcCtD
Pomalidomide—Decreased appetite—Dorzolamide—glaucoma	0.00023	0.00148	CcSEcCtD
Pomalidomide—Tremor—Clonidine—glaucoma	0.000229	0.00147	CcSEcCtD
Pomalidomide—Pruritus—Apraclonidine—glaucoma	0.000228	0.00147	CcSEcCtD
Pomalidomide—Body temperature increased—Acetazolamide—glaucoma	0.000228	0.00147	CcSEcCtD
Pomalidomide—Fatigue—Dorzolamide—glaucoma	0.000228	0.00147	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Pilocarpine—glaucoma	0.000228	0.00146	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Travoprost—glaucoma	0.000228	0.00146	CcSEcCtD
Pomalidomide—Fatigue—Travoprost—glaucoma	0.000227	0.00146	CcSEcCtD
Pomalidomide—Cardiac disorder—Betaxolol—glaucoma	0.000227	0.00146	CcSEcCtD
Pomalidomide—Pain—Dorzolamide—glaucoma	0.000226	0.00146	CcSEcCtD
Pomalidomide—Insomnia—Pilocarpine—glaucoma	0.000226	0.00145	CcSEcCtD
Pomalidomide—Decreased appetite—Brinzolamide—glaucoma	0.000226	0.00145	CcSEcCtD
Pomalidomide—Weight decreased—Timolol—glaucoma	0.000226	0.00145	CcSEcCtD
Pomalidomide—Pain—Travoprost—glaucoma	0.000225	0.00145	CcSEcCtD
Pomalidomide—Constipation—Travoprost—glaucoma	0.000225	0.00145	CcSEcCtD
Pomalidomide—Hyperglycaemia—Timolol—glaucoma	0.000225	0.00145	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Brinzolamide—glaucoma	0.000225	0.00144	CcSEcCtD
Pomalidomide—Asthenia—Bimatoprost—glaucoma	0.000225	0.00144	CcSEcCtD
Pomalidomide—Fatigue—Brinzolamide—glaucoma	0.000224	0.00144	CcSEcCtD
Pomalidomide—Dyspnoea—Pilocarpine—glaucoma	0.000223	0.00143	CcSEcCtD
Pomalidomide—Pain—Brinzolamide—glaucoma	0.000223	0.00143	CcSEcCtD
Pomalidomide—Angiopathy—Betaxolol—glaucoma	0.000222	0.00143	CcSEcCtD
Pomalidomide—Pruritus—Bimatoprost—glaucoma	0.000221	0.00142	CcSEcCtD
Pomalidomide—Diarrhoea—Apraclonidine—glaucoma	0.000221	0.00142	CcSEcCtD
Pomalidomide—Mediastinal disorder—Betaxolol—glaucoma	0.000221	0.00142	CcSEcCtD
Pomalidomide—Chills—Betaxolol—glaucoma	0.00022	0.00141	CcSEcCtD
Pomalidomide—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—glaucoma	0.000219	0.00476	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Dorzolamide—glaucoma	0.000218	0.0014	CcSEcCtD
Pomalidomide—TNF—Matrix Metalloproteinases—MMP9—glaucoma	0.000218	0.00475	CbGpPWpGaD
Pomalidomide—Decreased appetite—Pilocarpine—glaucoma	0.000217	0.0014	CcSEcCtD
Pomalidomide—Feeling abnormal—Travoprost—glaucoma	0.000217	0.0014	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Pilocarpine—glaucoma	0.000216	0.00139	CcSEcCtD
Pomalidomide—Feeling abnormal—Brinzolamide—glaucoma	0.000214	0.00138	CcSEcCtD
Pomalidomide—Mental disorder—Betaxolol—glaucoma	0.000214	0.00138	CcSEcCtD
Pomalidomide—Pain—Pilocarpine—glaucoma	0.000214	0.00137	CcSEcCtD
Pomalidomide—Constipation—Pilocarpine—glaucoma	0.000214	0.00137	CcSEcCtD
Pomalidomide—Cough—Clonidine—glaucoma	0.000214	0.00137	CcSEcCtD
Pomalidomide—Dizziness—Apraclonidine—glaucoma	0.000213	0.00137	CcSEcCtD
Pomalidomide—Malnutrition—Betaxolol—glaucoma	0.000213	0.00137	CcSEcCtD
Pomalidomide—Epistaxis—Timolol—glaucoma	0.00021	0.00135	CcSEcCtD
Pomalidomide—Body temperature increased—Dorzolamide—glaucoma	0.000209	0.00135	CcSEcCtD
Pomalidomide—Arthralgia—Clonidine—glaucoma	0.000208	0.00134	CcSEcCtD
Pomalidomide—TNF—Selenium Micronutrient Network—SOD1—glaucoma	0.000208	0.00453	CbGpPWpGaD
Pomalidomide—Anxiety—Clonidine—glaucoma	0.000208	0.00133	CcSEcCtD
Pomalidomide—TNF—Folate Metabolism—MTHFR—glaucoma	0.000207	0.00452	CbGpPWpGaD
Pomalidomide—Asthenia—Acetazolamide—glaucoma	0.000207	0.00133	CcSEcCtD
Pomalidomide—PTGS2—Spinal Cord Injury—C1QB—glaucoma	0.000207	0.00451	CbGpPWpGaD
Pomalidomide—TNF—amb2 Integrin signaling—MMP9—glaucoma	0.000207	0.00451	CbGpPWpGaD
Pomalidomide—Dizziness—Bimatoprost—glaucoma	0.000207	0.00133	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Clonidine—glaucoma	0.000207	0.00133	CcSEcCtD
Pomalidomide—Feeling abnormal—Pilocarpine—glaucoma	0.000206	0.00132	CcSEcCtD
Pomalidomide—Vomiting—Apraclonidine—glaucoma	0.000205	0.00132	CcSEcCtD
Pomalidomide—Muscle spasms—Betaxolol—glaucoma	0.000205	0.00132	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—IL1A—glaucoma	0.000204	0.00445	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Brimonidine—glaucoma	0.000204	0.00131	CcSEcCtD
Pomalidomide—Dermatitis—Apraclonidine—glaucoma	0.000203	0.00131	CcSEcCtD
Pomalidomide—Headache—Apraclonidine—glaucoma	0.000202	0.0013	CcSEcCtD
Pomalidomide—Confusional state—Clonidine—glaucoma	0.000201	0.00129	CcSEcCtD
Pomalidomide—PTGS2—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—VEGFA—glaucoma	0.0002	0.00436	CbGpPWpGaD
Pomalidomide—Tremor—Betaxolol—glaucoma	0.0002	0.00128	CcSEcCtD
Pomalidomide—Asthenia—Brimonidine—glaucoma	0.000199	0.00128	CcSEcCtD
Pomalidomide—Infection—Clonidine—glaucoma	0.000198	0.00128	CcSEcCtD
Pomalidomide—CYP1A2—Melatonin metabolism and effects—CYP1B1—glaucoma	0.000198	0.00432	CbGpPWpGaD
Pomalidomide—CYP3A4—Tamoxifen metabolism—CYP1B1—glaucoma	0.000198	0.00432	CbGpPWpGaD
Pomalidomide—Body temperature increased—Pilocarpine—glaucoma	0.000198	0.00127	CcSEcCtD
Pomalidomide—Diarrhoea—Acetazolamide—glaucoma	0.000198	0.00127	CcSEcCtD
Pomalidomide—Rash—Bimatoprost—glaucoma	0.000197	0.00127	CcSEcCtD
Pomalidomide—Dermatitis—Bimatoprost—glaucoma	0.000197	0.00127	CcSEcCtD
Pomalidomide—Oedema peripheral—Timolol—glaucoma	0.000197	0.00127	CcSEcCtD
Pomalidomide—Anaemia—Betaxolol—glaucoma	0.000197	0.00127	CcSEcCtD
Pomalidomide—Connective tissue disorder—Timolol—glaucoma	0.000196	0.00126	CcSEcCtD
Pomalidomide—Pruritus—Brimonidine—glaucoma	0.000196	0.00126	CcSEcCtD
Pomalidomide—Headache—Bimatoprost—glaucoma	0.000196	0.00126	CcSEcCtD
Pomalidomide—Nervous system disorder—Clonidine—glaucoma	0.000196	0.00126	CcSEcCtD
Pomalidomide—TNF—MicroRNAs in cardiomyocyte hypertrophy—EDN1—glaucoma	0.000196	0.00426	CbGpPWpGaD
Pomalidomide—Thrombocytopenia—Clonidine—glaucoma	0.000196	0.00126	CcSEcCtD
Pomalidomide—Hypersensitivity—Dorzolamide—glaucoma	0.000195	0.00125	CcSEcCtD
Pomalidomide—Hypersensitivity—Travoprost—glaucoma	0.000194	0.00125	CcSEcCtD
Pomalidomide—Skin disorder—Clonidine—glaucoma	0.000194	0.00125	CcSEcCtD
Pomalidomide—Hyperhidrosis—Clonidine—glaucoma	0.000193	0.00124	CcSEcCtD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—MMP2—glaucoma	0.000193	0.0042	CbGpPWpGaD
Pomalidomide—Nausea—Apraclonidine—glaucoma	0.000192	0.00123	CcSEcCtD
Pomalidomide—Hypersensitivity—Brinzolamide—glaucoma	0.000192	0.00123	CcSEcCtD
Pomalidomide—Vertigo—Betaxolol—glaucoma	0.000191	0.00123	CcSEcCtD
Pomalidomide—Dizziness—Acetazolamide—glaucoma	0.000191	0.00123	CcSEcCtD
Pomalidomide—Asthenia—Dorzolamide—glaucoma	0.00019	0.00122	CcSEcCtD
Pomalidomide—Asthenia—Travoprost—glaucoma	0.000189	0.00122	CcSEcCtD
Pomalidomide—Pruritus—Dorzolamide—glaucoma	0.000187	0.0012	CcSEcCtD
Pomalidomide—Asthenia—Brinzolamide—glaucoma	0.000187	0.0012	CcSEcCtD
Pomalidomide—Pruritus—Travoprost—glaucoma	0.000186	0.0012	CcSEcCtD
Pomalidomide—Cough—Betaxolol—glaucoma	0.000186	0.0012	CcSEcCtD
Pomalidomide—Nausea—Bimatoprost—glaucoma	0.000186	0.0012	CcSEcCtD
Pomalidomide—Cardiac disorder—Timolol—glaucoma	0.000186	0.00119	CcSEcCtD
Pomalidomide—Hypersensitivity—Pilocarpine—glaucoma	0.000184	0.00118	CcSEcCtD
Pomalidomide—Pruritus—Brinzolamide—glaucoma	0.000184	0.00118	CcSEcCtD
Pomalidomide—Vomiting—Acetazolamide—glaucoma	0.000184	0.00118	CcSEcCtD
Pomalidomide—Dizziness—Brimonidine—glaucoma	0.000183	0.00118	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—FAS—glaucoma	0.000182	0.00397	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—FAS—glaucoma	0.000182	0.00397	CbGpPWpGaD
Pomalidomide—Musculoskeletal discomfort—Clonidine—glaucoma	0.000182	0.00117	CcSEcCtD
Pomalidomide—Angiopathy—Timolol—glaucoma	0.000181	0.00117	CcSEcCtD
Pomalidomide—Arthralgia—Betaxolol—glaucoma	0.000181	0.00117	CcSEcCtD
Pomalidomide—Diarrhoea—Dorzolamide—glaucoma	0.000181	0.00116	CcSEcCtD
Pomalidomide—Headache—Acetazolamide—glaucoma	0.000181	0.00116	CcSEcCtD
Pomalidomide—Anxiety—Betaxolol—glaucoma	0.000181	0.00116	CcSEcCtD
Pomalidomide—Insomnia—Clonidine—glaucoma	0.000181	0.00116	CcSEcCtD
Pomalidomide—TNF—Angiopoietin receptor Tie2-mediated signaling—NOS3—glaucoma	0.000181	0.00393	CbGpPWpGaD
Pomalidomide—Diarrhoea—Travoprost—glaucoma	0.00018	0.00116	CcSEcCtD
Pomalidomide—Mediastinal disorder—Timolol—glaucoma	0.00018	0.00116	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Betaxolol—glaucoma	0.00018	0.00116	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—C3—glaucoma	0.00018	0.00391	CbGpPWpGaD
Pomalidomide—Asthenia—Pilocarpine—glaucoma	0.000179	0.00115	CcSEcCtD
Pomalidomide—CYP3A4—Estrogen metabolism—GSTM1—glaucoma	0.000179	0.0039	CbGpPWpGaD
Pomalidomide—Dyspnoea—Clonidine—glaucoma	0.000178	0.00114	CcSEcCtD
Pomalidomide—Diarrhoea—Brinzolamide—glaucoma	0.000178	0.00114	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—NGFR—glaucoma	0.000177	0.00387	CbGpPWpGaD
Pomalidomide—Pruritus—Pilocarpine—glaucoma	0.000177	0.00114	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—PTGS2—glaucoma	0.000177	0.00385	CbGpPWpGaD
Pomalidomide—Confusional state—Betaxolol—glaucoma	0.000175	0.00113	CcSEcCtD
Pomalidomide—Mental disorder—Timolol—glaucoma	0.000175	0.00113	CcSEcCtD
Pomalidomide—Dizziness—Dorzolamide—glaucoma	0.000175	0.00113	CcSEcCtD
Pomalidomide—Rash—Brimonidine—glaucoma	0.000175	0.00112	CcSEcCtD
Pomalidomide—Dermatitis—Brimonidine—glaucoma	0.000175	0.00112	CcSEcCtD
Pomalidomide—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—glaucoma	0.000175	0.0038	CbGpPWpGaD
Pomalidomide—PTGS2—S1P1 pathway—VEGFA—glaucoma	0.000174	0.0038	CbGpPWpGaD
Pomalidomide—Dizziness—Travoprost—glaucoma	0.000174	0.00112	CcSEcCtD
Pomalidomide—Malnutrition—Timolol—glaucoma	0.000174	0.00112	CcSEcCtD
Pomalidomide—Headache—Brimonidine—glaucoma	0.000174	0.00112	CcSEcCtD
Pomalidomide—Decreased appetite—Clonidine—glaucoma	0.000174	0.00112	CcSEcCtD
Pomalidomide—TNF—Apoptosis—FAS—glaucoma	0.000173	0.00378	CbGpPWpGaD
Pomalidomide—Infection—Betaxolol—glaucoma	0.000173	0.00111	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Clonidine—glaucoma	0.000172	0.00111	CcSEcCtD
Pomalidomide—Fatigue—Clonidine—glaucoma	0.000172	0.00111	CcSEcCtD
Pomalidomide—Dizziness—Brinzolamide—glaucoma	0.000172	0.00111	CcSEcCtD
Pomalidomide—Nausea—Acetazolamide—glaucoma	0.000172	0.0011	CcSEcCtD
Pomalidomide—Diarrhoea—Pilocarpine—glaucoma	0.000171	0.0011	CcSEcCtD
Pomalidomide—Constipation—Clonidine—glaucoma	0.000171	0.0011	CcSEcCtD
Pomalidomide—Pain—Clonidine—glaucoma	0.000171	0.0011	CcSEcCtD
Pomalidomide—Nervous system disorder—Betaxolol—glaucoma	0.000171	0.0011	CcSEcCtD
Pomalidomide—Thrombocytopenia—Betaxolol—glaucoma	0.00017	0.00109	CcSEcCtD
Pomalidomide—Skin disorder—Betaxolol—glaucoma	0.000169	0.00109	CcSEcCtD
Pomalidomide—Vomiting—Dorzolamide—glaucoma	0.000168	0.00108	CcSEcCtD
Pomalidomide—Hyperhidrosis—Betaxolol—glaucoma	0.000168	0.00108	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor Pathway—CDKN1B—glaucoma	0.000167	0.00364	CbGpPWpGaD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—CDKN1B—glaucoma	0.000167	0.00364	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—APOE—glaucoma	0.000167	0.00364	CbGpPWpGaD
Pomalidomide—Rash—Dorzolamide—glaucoma	0.000167	0.00107	CcSEcCtD
Pomalidomide—Dermatitis—Dorzolamide—glaucoma	0.000167	0.00107	CcSEcCtD
Pomalidomide—TNF—TWEAK Signaling Pathway—MMP9—glaucoma	0.000167	0.00363	CbGpPWpGaD
Pomalidomide—Rash—Travoprost—glaucoma	0.000166	0.00107	CcSEcCtD
Pomalidomide—Dermatitis—Travoprost—glaucoma	0.000166	0.00107	CcSEcCtD
Pomalidomide—Headache—Dorzolamide—glaucoma	0.000166	0.00107	CcSEcCtD
Pomalidomide—Vomiting—Brinzolamide—glaucoma	0.000165	0.00106	CcSEcCtD
Pomalidomide—TNF—SIDS Susceptibility Pathways—NTRK2—glaucoma	0.000165	0.0036	CbGpPWpGaD
Pomalidomide—Dizziness—Pilocarpine—glaucoma	0.000165	0.00106	CcSEcCtD
Pomalidomide—TNF—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PTGS2—glaucoma	0.000165	0.0036	CbGpPWpGaD
Pomalidomide—Headache—Travoprost—glaucoma	0.000165	0.00106	CcSEcCtD
Pomalidomide—TNF—Selenium Micronutrient Network—MTHFR—glaucoma	0.000165	0.00359	CbGpPWpGaD
Pomalidomide—Nausea—Brimonidine—glaucoma	0.000165	0.00106	CcSEcCtD
Pomalidomide—Feeling abnormal—Clonidine—glaucoma	0.000165	0.00106	CcSEcCtD
Pomalidomide—Rash—Brinzolamide—glaucoma	0.000164	0.00105	CcSEcCtD
Pomalidomide—Dermatitis—Brinzolamide—glaucoma	0.000164	0.00105	CcSEcCtD
Pomalidomide—TNF—Apoptosis—BCL2L1—glaucoma	0.000164	0.00356	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—TGFB2—glaucoma	0.000163	0.00356	CbGpPWpGaD
Pomalidomide—Headache—Brinzolamide—glaucoma	0.000163	0.00105	CcSEcCtD
Pomalidomide—CYP1A2—Melatonin metabolism and effects—EDN1—glaucoma	0.00016	0.00349	CbGpPWpGaD
Pomalidomide—Vomiting—Pilocarpine—glaucoma	0.000159	0.00102	CcSEcCtD
Pomalidomide—Musculoskeletal discomfort—Betaxolol—glaucoma	0.000158	0.00102	CcSEcCtD
Pomalidomide—Body temperature increased—Clonidine—glaucoma	0.000158	0.00102	CcSEcCtD
Pomalidomide—Rash—Pilocarpine—glaucoma	0.000158	0.00101	CcSEcCtD
Pomalidomide—Dermatitis—Pilocarpine—glaucoma	0.000158	0.00101	CcSEcCtD
Pomalidomide—Insomnia—Betaxolol—glaucoma	0.000157	0.00101	CcSEcCtD
Pomalidomide—Nausea—Dorzolamide—glaucoma	0.000157	0.00101	CcSEcCtD
Pomalidomide—Headache—Pilocarpine—glaucoma	0.000157	0.00101	CcSEcCtD
Pomalidomide—Nausea—Travoprost—glaucoma	0.000157	0.00101	CcSEcCtD
Pomalidomide—Vertigo—Timolol—glaucoma	0.000156	0.00101	CcSEcCtD
Pomalidomide—TNF—Alzheimers Disease—BAD—glaucoma	0.000156	0.00339	CbGpPWpGaD
Pomalidomide—Dyspnoea—Betaxolol—glaucoma	0.000155	0.000997	CcSEcCtD
Pomalidomide—Nausea—Brinzolamide—glaucoma	0.000155	0.000994	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—BDNF—glaucoma	0.000154	0.00336	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—SMO—glaucoma	0.000154	0.00335	CbGpPWpGaD
Pomalidomide—TNF—TNF alpha Signaling Pathway—BCL2L1—glaucoma	0.000152	0.00331	CbGpPWpGaD
Pomalidomide—Cough—Timolol—glaucoma	0.000152	0.000976	CcSEcCtD
Pomalidomide—Decreased appetite—Betaxolol—glaucoma	0.000151	0.000972	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Betaxolol—glaucoma	0.00015	0.000965	CcSEcCtD
Pomalidomide—Fatigue—Betaxolol—glaucoma	0.00015	0.000964	CcSEcCtD
Pomalidomide—PTGS2—Overview of nanoparticle effects—TNF—glaucoma	0.00015	0.00326	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis-related network due to altered Notch3 in ovarian cancer—CDKN1B—glaucoma	0.000149	0.00325	CbGpPWpGaD
Pomalidomide—Pain—Betaxolol—glaucoma	0.000149	0.000956	CcSEcCtD
Pomalidomide—Constipation—Betaxolol—glaucoma	0.000149	0.000956	CcSEcCtD
Pomalidomide—Nausea—Pilocarpine—glaucoma	0.000149	0.000955	CcSEcCtD
Pomalidomide—TNF—Apoptosis—BAD—glaucoma	0.000148	0.00323	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—IL1A—glaucoma	0.000148	0.00323	CbGpPWpGaD
Pomalidomide—Arthralgia—Timolol—glaucoma	0.000148	0.000953	CcSEcCtD
Pomalidomide—Anxiety—Timolol—glaucoma	0.000148	0.000949	CcSEcCtD
Pomalidomide—Unspecified disorder of skin and subcutaneous tissue—Timolol—glaucoma	0.000147	0.000946	CcSEcCtD
Pomalidomide—Hypersensitivity—Clonidine—glaucoma	0.000147	0.000946	CcSEcCtD
Pomalidomide—PTGS2—Selenium Micronutrient Network—ABCA1—glaucoma	0.000144	0.00314	CbGpPWpGaD
Pomalidomide—Asthenia—Clonidine—glaucoma	0.000143	0.000921	CcSEcCtD
Pomalidomide—Feeling abnormal—Betaxolol—glaucoma	0.000143	0.000921	CcSEcCtD
Pomalidomide—Confusional state—Timolol—glaucoma	0.000143	0.000921	CcSEcCtD
Pomalidomide—Pruritus—Clonidine—glaucoma	0.000141	0.000908	CcSEcCtD
Pomalidomide—Infection—Timolol—glaucoma	0.000141	0.000907	CcSEcCtD
Pomalidomide—Nervous system disorder—Timolol—glaucoma	0.000139	0.000896	CcSEcCtD
Pomalidomide—TNF—Aryl Hydrocarbon Receptor—VEGFA—glaucoma	0.000139	0.00303	CbGpPWpGaD
Pomalidomide—Skin disorder—Timolol—glaucoma	0.000138	0.000887	CcSEcCtD
Pomalidomide—TNF—TNF alpha Signaling Pathway—BAD—glaucoma	0.000138	0.003	CbGpPWpGaD
Pomalidomide—Body temperature increased—Betaxolol—glaucoma	0.000137	0.000884	CcSEcCtD
Pomalidomide—Hyperhidrosis—Timolol—glaucoma	0.000137	0.000883	CcSEcCtD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—CYP1B1—glaucoma	0.000137	0.00299	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CYP1B1—glaucoma	0.000137	0.00299	CbGpPWpGaD
Pomalidomide—CYP1A2—Tryptophan metabolism—CYP1B1—glaucoma	0.000137	0.00299	CbGpPWpGaD
Pomalidomide—Diarrhoea—Clonidine—glaucoma	0.000137	0.000879	CcSEcCtD
Pomalidomide—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCA1—glaucoma	0.000135	0.00294	CbGpPWpGaD
Pomalidomide—Dizziness—Clonidine—glaucoma	0.000132	0.000849	CcSEcCtD
Pomalidomide—CYP1A2—Melatonin metabolism and effects—APOE—glaucoma	0.00013	0.00284	CbGpPWpGaD
Pomalidomide—Musculoskeletal discomfort—Timolol—glaucoma	0.000129	0.000832	CcSEcCtD
Pomalidomide—PTGS2—Selenium Micronutrient Network—SOD1—glaucoma	0.000129	0.0028	CbGpPWpGaD
Pomalidomide—Insomnia—Timolol—glaucoma	0.000128	0.000826	CcSEcCtD
Pomalidomide—CYP1A2—Arachidonic acid metabolism—CYP1B1—glaucoma	0.000128	0.00279	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Betaxolol—glaucoma	0.000128	0.000824	CcSEcCtD
Pomalidomide—TNF—MAPK Signaling Pathway—NTRK1—glaucoma	0.000127	0.00277	CbGpPWpGaD
Pomalidomide—Vomiting—Clonidine—glaucoma	0.000127	0.000816	CcSEcCtD
Pomalidomide—Dyspnoea—Timolol—glaucoma	0.000127	0.000814	CcSEcCtD
Pomalidomide—TNF—Adipogenesis—NR3C1—glaucoma	0.000126	0.00275	CbGpPWpGaD
Pomalidomide—Rash—Clonidine—glaucoma	0.000126	0.00081	CcSEcCtD
Pomalidomide—Dermatitis—Clonidine—glaucoma	0.000126	0.000809	CcSEcCtD
Pomalidomide—Headache—Clonidine—glaucoma	0.000125	0.000804	CcSEcCtD
Pomalidomide—Asthenia—Betaxolol—glaucoma	0.000125	0.000802	CcSEcCtD
Pomalidomide—Decreased appetite—Timolol—glaucoma	0.000123	0.000794	CcSEcCtD
Pomalidomide—TNF—SIDS Susceptibility Pathways—BDNF—glaucoma	0.000123	0.00269	CbGpPWpGaD
Pomalidomide—Pruritus—Betaxolol—glaucoma	0.000123	0.000791	CcSEcCtD
Pomalidomide—Gastrointestinal disorder—Timolol—glaucoma	0.000123	0.000788	CcSEcCtD
Pomalidomide—Fatigue—Timolol—glaucoma	0.000122	0.000787	CcSEcCtD
Pomalidomide—TNF—Amyotrophic lateral sclerosis (ALS)—TP53—glaucoma	0.000122	0.00267	CbGpPWpGaD
Pomalidomide—TNF—Adipogenesis—FAS—glaucoma	0.000122	0.00266	CbGpPWpGaD
Pomalidomide—Pain—Timolol—glaucoma	0.000121	0.000781	CcSEcCtD
Pomalidomide—PTGS2—C-MYB transcription factor network—GSTM1—glaucoma	0.00012	0.00261	CbGpPWpGaD
Pomalidomide—Diarrhoea—Betaxolol—glaucoma	0.000119	0.000765	CcSEcCtD
Pomalidomide—Nausea—Clonidine—glaucoma	0.000119	0.000763	CcSEcCtD
Pomalidomide—TNF—SIDS Susceptibility Pathways—IL1A—glaucoma	0.000119	0.00258	CbGpPWpGaD
Pomalidomide—Feeling abnormal—Timolol—glaucoma	0.000117	0.000753	CcSEcCtD
Pomalidomide—TNF—Apoptosis—CDKN2A—glaucoma	0.000117	0.00254	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—BDNF—glaucoma	0.000116	0.00254	CbGpPWpGaD
Pomalidomide—Dizziness—Betaxolol—glaucoma	0.000115	0.000739	CcSEcCtD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—NTRK1—glaucoma	0.000115	0.0025	CbGpPWpGaD
Pomalidomide—Body temperature increased—Timolol—glaucoma	0.000112	0.000722	CcSEcCtD
Pomalidomide—TNF—MAPK Signaling Pathway—IL1A—glaucoma	0.000112	0.00243	CbGpPWpGaD
Pomalidomide—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP1B1—glaucoma	0.000111	0.00241	CbGpPWpGaD
Pomalidomide—Vomiting—Betaxolol—glaucoma	0.000111	0.000711	CcSEcCtD
Pomalidomide—PTGS2—Spinal Cord Injury—NGFR—glaucoma	0.00011	0.00239	CbGpPWpGaD
Pomalidomide—Rash—Betaxolol—glaucoma	0.00011	0.000705	CcSEcCtD
Pomalidomide—TNF—SIDS Susceptibility Pathways—NGF—glaucoma	0.00011	0.00239	CbGpPWpGaD
Pomalidomide—Dermatitis—Betaxolol—glaucoma	0.00011	0.000704	CcSEcCtD
Pomalidomide—CYP1A2—Oxidation by Cytochrome P450—CYP1B1—glaucoma	0.000109	0.00238	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—NR3C1—glaucoma	0.000109	0.00238	CbGpPWpGaD
Pomalidomide—Headache—Betaxolol—glaucoma	0.000109	0.0007	CcSEcCtD
Pomalidomide—TNF—Developmental Biology—NCK2—glaucoma	0.000108	0.00236	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—FAS—glaucoma	0.000106	0.00231	CbGpPWpGaD
Pomalidomide—CYP3A4—Tryptophan metabolism—CYP1B1—glaucoma	0.000106	0.0023	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CDKN2B—glaucoma	0.000106	0.0023	CbGpPWpGaD
Pomalidomide—TNF—Selenium Micronutrient Network—PTGS2—glaucoma	0.000105	0.00229	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—BDNF—glaucoma	0.000105	0.00229	CbGpPWpGaD
Pomalidomide—Hypersensitivity—Timolol—glaucoma	0.000105	0.000673	CcSEcCtD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—EDN1—glaucoma	0.000104	0.00227	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—CDKN1B—glaucoma	0.000103	0.00225	CbGpPWpGaD
Pomalidomide—Nausea—Betaxolol—glaucoma	0.000103	0.000664	CcSEcCtD
Pomalidomide—TNF—MAPK Signaling Pathway—NGF—glaucoma	0.000103	0.00225	CbGpPWpGaD
Pomalidomide—PTGS2—Defective AMN causes hereditary megaloblastic anemia 1—MTHFR—glaucoma	0.000103	0.00224	CbGpPWpGaD
Pomalidomide—CYP1A2—Phase II conjugation—GSTT1—glaucoma	0.000102	0.00223	CbGpPWpGaD
Pomalidomide—Asthenia—Timolol—glaucoma	0.000102	0.000655	CcSEcCtD
Pomalidomide—PTGS2—Selenium Micronutrient Network—MTHFR—glaucoma	0.000102	0.00222	CbGpPWpGaD
Pomalidomide—Pruritus—Timolol—glaucoma	0.000101	0.000646	CcSEcCtD
Pomalidomide—TNF—Apoptosis—BCL2L1—glaucoma	0.0001	0.00218	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—FAS—glaucoma	9.96e-05	0.00217	CbGpPWpGaD
Pomalidomide—Diarrhoea—Timolol—glaucoma	9.72e-05	0.000625	CcSEcCtD
Pomalidomide—PTGS2—Spinal Cord Injury—BDNF—glaucoma	9.55e-05	0.00208	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—PEX19—glaucoma	9.55e-05	0.00208	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—SMO—glaucoma	9.51e-05	0.00207	CbGpPWpGaD
Pomalidomide—Dizziness—Timolol—glaucoma	9.39e-05	0.000604	CcSEcCtD
Pomalidomide—PTGS2—Spinal Cord Injury—IL1A—glaucoma	9.17e-05	0.002	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—BAD—glaucoma	9.08e-05	0.00198	CbGpPWpGaD
Pomalidomide—Vomiting—Timolol—glaucoma	9.03e-05	0.000581	CcSEcCtD
Pomalidomide—TNF—Allograft Rejection—VEGFA—glaucoma	9.02e-05	0.00197	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—FAS—glaucoma	8.99e-05	0.00196	CbGpPWpGaD
Pomalidomide—CYP1A2—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	8.99e-05	0.00196	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—IL1A—glaucoma	8.96e-05	0.00195	CbGpPWpGaD
Pomalidomide—Rash—Timolol—glaucoma	8.96e-05	0.000576	CcSEcCtD
Pomalidomide—Dermatitis—Timolol—glaucoma	8.95e-05	0.000575	CcSEcCtD
Pomalidomide—Headache—Timolol—glaucoma	8.9e-05	0.000572	CcSEcCtD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—VEGFA—glaucoma	8.6e-05	0.00187	CbGpPWpGaD
Pomalidomide—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP1B1—glaucoma	8.55e-05	0.00186	CbGpPWpGaD
Pomalidomide—CYP3A4—Oxidation by Cytochrome P450—CYP1B1—glaucoma	8.44e-05	0.00184	CbGpPWpGaD
Pomalidomide—Nausea—Timolol—glaucoma	8.44e-05	0.000542	CcSEcCtD
Pomalidomide—TNF—Spinal Cord Injury—PTGS2—glaucoma	8.31e-05	0.00181	CbGpPWpGaD
Pomalidomide—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—glaucoma	8.09e-05	0.00176	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—FAS—glaucoma	7.98e-05	0.00174	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CTSA—glaucoma	7.88e-05	0.00172	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—C3—glaucoma	7.87e-05	0.00171	CbGpPWpGaD
Pomalidomide—TNF—Folate Metabolism—TP53—glaucoma	7.87e-05	0.00171	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—CDKN1B—glaucoma	7.87e-05	0.00171	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—BAD—glaucoma	7.69e-05	0.00167	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CA5A—glaucoma	7.42e-05	0.00162	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—NARFL—glaucoma	7.42e-05	0.00162	CbGpPWpGaD
Pomalidomide—PTGS2—Aryl Hydrocarbon Receptor—TNF—glaucoma	7.37e-05	0.00161	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—MMP9—glaucoma	7.29e-05	0.00159	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—CDKN2A—glaucoma	7.21e-05	0.00157	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—NTRK1—glaucoma	7.09e-05	0.00155	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—PAX6—glaucoma	7e-05	0.00153	CbGpPWpGaD
Pomalidomide—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—glaucoma	6.97e-05	0.00152	CbGpPWpGaD
Pomalidomide—CYP3A4—Phase 1 - Functionalization of compounds—CYP1B1—glaucoma	6.93e-05	0.00151	CbGpPWpGaD
Pomalidomide—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—glaucoma	6.9e-05	0.0015	CbGpPWpGaD
Pomalidomide—TNF—Alzheimers Disease—TP53—glaucoma	6.82e-05	0.00149	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—glaucoma	6.74e-05	0.00147	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—LRP12—glaucoma	6.71e-05	0.00146	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN2B—glaucoma	6.54e-05	0.00142	CbGpPWpGaD
Pomalidomide—CYP1A2—Phase II conjugation—GSTM1—glaucoma	6.52e-05	0.00142	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BDNF—glaucoma	6.49e-05	0.00141	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—glaucoma	6.49e-05	0.00141	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—SLC4A4—glaucoma	6.45e-05	0.0014	CbGpPWpGaD
Pomalidomide—PTGS2—C-MYB transcription factor network—CDKN1B—glaucoma	6.39e-05	0.00139	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—glaucoma	6.18e-05	0.00135	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—GSTT1—glaucoma	5.99e-05	0.0013	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—CDKN1B—glaucoma	5.85e-05	0.00127	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1B—glaucoma	5.85e-05	0.00127	CbGpPWpGaD
Pomalidomide—CYP1A2—Arachidonic acid metabolism—PTGS2—glaucoma	5.78e-05	0.00126	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—PTGS2—glaucoma	5.65e-05	0.00123	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—FAS—glaucoma	5.56e-05	0.00121	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—CDKN1B—glaucoma	5.35e-05	0.00117	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NARFL—glaucoma	5.26e-05	0.00115	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CA5A—glaucoma	5.26e-05	0.00115	CbGpPWpGaD
Pomalidomide—TNF—SIDS Susceptibility Pathways—VEGFA—glaucoma	5.23e-05	0.00114	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—NTRK1—glaucoma	5.03e-05	0.0011	CbGpPWpGaD
Pomalidomide—TNF—Spinal Cord Injury—TP53—glaucoma	4.95e-05	0.00108	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—CDKN1B—glaucoma	4.87e-05	0.00106	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—VEGFA—glaucoma	4.87e-05	0.00106	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—CYP1B1—glaucoma	4.77e-05	0.00104	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—BAD—glaucoma	4.75e-05	0.00104	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—CYP1B1—glaucoma	4.71e-05	0.00103	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—glaucoma	4.63e-05	0.00101	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—GSTT1—glaucoma	4.62e-05	0.00101	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BDNF—glaucoma	4.6e-05	0.001	CbGpPWpGaD
Pomalidomide—ABCB1—HIF-1-alpha transcription factor network—VEGFA—glaucoma	4.57e-05	0.000995	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—MMP9—glaucoma	4.51e-05	0.000982	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CTSA—glaucoma	4.46e-05	0.000971	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	4.45e-05	0.00097	CbGpPWpGaD
Pomalidomide—PTGS2—Selenium Micronutrient Network—TNF—glaucoma	4.39e-05	0.000956	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—FGFR1OP—glaucoma	4.33e-05	0.000942	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HEYL—glaucoma	4.33e-05	0.000942	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—SLC6A13—glaucoma	4.3e-05	0.000937	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CA5A—glaucoma	4.2e-05	0.000915	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NARFL—glaucoma	4.2e-05	0.000915	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor—TNF—glaucoma	4.17e-05	0.000909	CbGpPWpGaD
Pomalidomide—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—glaucoma	4.17e-05	0.000909	CbGpPWpGaD
Pomalidomide—TNF—Apoptosis—TP53—glaucoma	3.98e-05	0.000866	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—VEGFA—glaucoma	3.96e-05	0.000862	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—glaucoma	3.94e-05	0.000858	CbGpPWpGaD
Pomalidomide—CYP1A2—Biological oxidations—GSTM1—glaucoma	3.82e-05	0.000831	CbGpPWpGaD
Pomalidomide—CYP1A2—Metapathway biotransformation—GSTM1—glaucoma	3.76e-05	0.00082	CbGpPWpGaD
Pomalidomide—TNF—MAPK Signaling Pathway—TP53—glaucoma	3.73e-05	0.000812	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—CYP1B1—glaucoma	3.68e-05	0.000802	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—CYP1B1—glaucoma	3.63e-05	0.000791	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CA1—glaucoma	3.62e-05	0.000789	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CTSA—glaucoma	3.51e-05	0.000764	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TNF—glaucoma	3.47e-05	0.000756	CbGpPWpGaD
Pomalidomide—ABCB1—Allograft Rejection—TNF—glaucoma	3.39e-05	0.000738	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—BAD—glaucoma	3.37e-05	0.000734	CbGpPWpGaD
Pomalidomide—TNF—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	3.36e-05	0.000733	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CA2—glaucoma	3.31e-05	0.000722	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—CDKN1B—glaucoma	3.31e-05	0.000721	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CA5A—glaucoma	3.24e-05	0.000706	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NARFL—glaucoma	3.24e-05	0.000706	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	3.24e-05	0.000706	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	3.24e-05	0.000706	CbGpPWpGaD
Pomalidomide—ABCB1—Transmembrane transport of small molecules—SLC6A1—glaucoma	3.15e-05	0.000686	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MMP2—glaucoma	3.08e-05	0.000672	CbGpPWpGaD
Pomalidomide—PTGS2—Spinal Cord Injury—TP53—glaucoma	3.06e-05	0.000666	CbGpPWpGaD
Pomalidomide—CYP3A4—Biological oxidations—GSTM1—glaucoma	2.94e-05	0.000642	CbGpPWpGaD
Pomalidomide—CYP3A4—Metapathway biotransformation—GSTM1—glaucoma	2.9e-05	0.000633	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	2.75e-05	0.0006	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—HDAC9—glaucoma	2.7e-05	0.000588	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CA1—glaucoma	2.57e-05	0.00056	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CTSA—glaucoma	2.49e-05	0.000542	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—glaucoma	2.48e-05	0.00054	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	2.36e-05	0.000514	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CA2—glaucoma	2.35e-05	0.000512	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—glaucoma	2.35e-05	0.000511	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—TXN—glaucoma	2.33e-05	0.000509	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—MMP9—glaucoma	2.32e-05	0.000505	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—APOE—glaucoma	2.13e-05	0.000464	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism of lipids and lipoproteins—CAV1—glaucoma	2.11e-05	0.00046	CbGpPWpGaD
Pomalidomide—TNF—Developmental Biology—VEGFA—glaucoma	2.08e-05	0.000453	CbGpPWpGaD
Pomalidomide—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	2.08e-05	0.000453	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CA1—glaucoma	2.05e-05	0.000447	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CTSA—glaucoma	1.99e-05	0.000433	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—glaucoma	1.95e-05	0.000425	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CA2—glaucoma	1.88e-05	0.000409	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CYP1B1—glaucoma	1.83e-05	0.000399	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—ABCA1—glaucoma	1.83e-05	0.000399	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GSTT1—glaucoma	1.81e-05	0.000394	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—glaucoma	1.67e-05	0.000364	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—TXN—glaucoma	1.65e-05	0.000361	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CA1—glaucoma	1.58e-05	0.000345	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CTSA—glaucoma	1.53e-05	0.000334	CbGpPWpGaD
Pomalidomide—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—glaucoma	1.47e-05	0.000321	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CDKN2B—glaucoma	1.45e-05	0.000316	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CA2—glaucoma	1.45e-05	0.000315	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—ABCA1—glaucoma	1.44e-05	0.000314	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CYP1B1—glaucoma	1.44e-05	0.000314	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—TXN—glaucoma	1.32e-05	0.000288	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTT1—glaucoma	1.28e-05	0.00028	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—MTHFR—glaucoma	1.22e-05	0.000265	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—APOE—glaucoma	1.21e-05	0.000263	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—CAV1—glaucoma	1.19e-05	0.00026	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—GSTM1—glaucoma	1.15e-05	0.000251	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—APOE—glaucoma	1.13e-05	0.000247	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CAV1—glaucoma	1.12e-05	0.000245	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—BAD—glaucoma	1.06e-05	0.00023	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTT1—glaucoma	1.02e-05	0.000223	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—ABCA1—glaucoma	1.02e-05	0.000223	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CYP1B1—glaucoma	1.02e-05	0.000223	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—TXN—glaucoma	1.02e-05	0.000222	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—MTHFR—glaucoma	1.02e-05	0.000222	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—APOE—glaucoma	9.49e-06	0.000207	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—CAV1—glaucoma	9.4e-06	0.000205	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—NOS3—glaucoma	8.49e-06	0.000185	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—glaucoma	8.26e-06	0.00018	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—GSTM1—glaucoma	8.17e-06	0.000178	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CYP1B1—glaucoma	8.16e-06	0.000178	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—ABCA1—glaucoma	8.16e-06	0.000178	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTT1—glaucoma	7.91e-06	0.000172	CbGpPWpGaD
Pomalidomide—PTGS2—Disease—CDKN1B—glaucoma	7.35e-06	0.00016	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—MTHFR—glaucoma	7.22e-06	0.000157	CbGpPWpGaD
Pomalidomide—PTGS2—Metabolism—NOS3—glaucoma	7.11e-06	0.000155	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—APOE—glaucoma	6.73e-06	0.000147	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—CAV1—glaucoma	6.66e-06	0.000145	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—GSTM1—glaucoma	6.53e-06	0.000142	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—ABCA1—glaucoma	6.3e-06	0.000137	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CYP1B1—glaucoma	6.3e-06	0.000137	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—MTHFR—glaucoma	5.77e-06	0.000126	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—APOE—glaucoma	5.37e-06	0.000117	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—CAV1—glaucoma	5.32e-06	0.000116	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—NOS3—glaucoma	5.04e-06	0.00011	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—GSTM1—glaucoma	5.04e-06	0.00011	CbGpPWpGaD
Pomalidomide—ABCB1—Metabolism—PTGS2—glaucoma	4.61e-06	0.0001	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—MTHFR—glaucoma	4.45e-06	9.7e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—APOE—glaucoma	4.14e-06	9.03e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—CAV1—glaucoma	4.11e-06	8.94e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—NOS3—glaucoma	4.02e-06	8.76e-05	CbGpPWpGaD
Pomalidomide—CYP1A2—Metabolism—PTGS2—glaucoma	3.68e-06	8.01e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—NOS3—glaucoma	3.1e-06	6.76e-05	CbGpPWpGaD
Pomalidomide—CYP3A4—Metabolism—PTGS2—glaucoma	2.84e-06	6.18e-05	CbGpPWpGaD
